The clone MYG13 recognizes CD22 cell surface antigen, a 130-140kDa protein. The expression of CD22 is primarily restricted to the normal and neoplastic B cells but does not express on other hematopoietic cells. The initiation of expression of CD22 starts in the cytoplasm of pro-B and pre-B cells. Although CD22 is not expressed by plasma cells, it is abundantly expressed by the follicular mantle and marginal zone B-cells. Being a member of the immunoglobulin superfamily, CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and leukocytes. The role of CD22 in the activation of B-cells is primarily associated with tyrosine kinases mediated signal transduction pathways.
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose.
BLK (Phospho-Tyr389) Antibody detects endogenous levels of BLK only when phosphorylated at Tyr389
Epitope:
Phospho Tyr389
Immunogen:
A synthesized peptide derived from human BLK (Phospho-Tyr389)
Cross Reactivity:
Human,Mouse,Rat
Conjugate:
Unconjugated
purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns.
Concentration:
1mg/ml
Fragment:
Fab fragment
Buffer:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose.
BLK (Phospho-Tyr389) Antibody detects endogenous levels of BLK only when phosphorylated at Tyr389
Epitope:
Phospho Tyr389
Immunogen:
A synthesized peptide derived from human BLK (Phospho-Tyr389)
Cross Reactivity:
Human,Mouse,Rat
Conjugate:
Unconjugated
purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns.
Concentration:
1mg/ml
Fragment:
Fab fragment
Buffer:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose.
BLK (Phospho-Tyr389) Antibody detects endogenous levels of BLK only when phosphorylated at Tyr389
Epitope:
Phospho Tyr389
Immunogen:
A synthesized peptide derived from human BLK (Phospho-Tyr389)
Cross Reactivity:
Human,Mouse,Rat
Conjugate:
Unconjugated
purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns.
Concentration:
1mg/ml
Fragment:
Fab fragment
Buffer:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose.
BLK antibody detects endogenous levels of total BLK.
Immunogen:
Purified recombinant fragment of human BLK expressed in E. Coli.
Cross Reactivity:
Human
Conjugate:
Unconjugated
purification:
Affinity-chromatography.
Concentration:
1mg/ml
Fragment:
Fab fragment
Buffer:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt.
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose.
BLK antibody detects endogenous levels of total BLK.
Immunogen:
Purified recombinant fragment of human BLK expressed in E. Coli.
Cross Reactivity:
Human
Conjugate:
Unconjugated
purification:
Affinity-chromatography.
Concentration:
1mg/ml
Fragment:
Fab fragment
Buffer:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt.
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose.
BLK antibody detects endogenous levels of total BLK.
Immunogen:
Purified recombinant fragment of human BLK expressed in E. Coli.
Cross Reactivity:
Human
Conjugate:
Unconjugated
purification:
Affinity-chromatography.
Concentration:
1mg/ml
Fragment:
Fab fragment
Buffer:
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt.
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose.
The antiserum was purified by peptide affinity chromatography using SulfoLink(TM) Coupling Resin (Thermo Fisher Scientific).
Concentration:
1mg/ml
Fragment:
Fab fragment
Buffer:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt
Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose.
The antiserum was purified by peptide affinity chromatography using SulfoLink(TM) Coupling Resin (Thermo Fisher Scientific).
Concentration:
1mg/ml
Fragment:
Fab fragment
Buffer:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
Applications:
WB | ICC/IF | IHC
Application Details:
WB (1:1000), IHC (1:100), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
Unconjugated
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
Applications:
WB | ICC/IF | IHC
Application Details:
WB (1:1000), IHC (1:100), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
Unconjugated
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.2, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog Calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
Applications:
WB | IHC | ICC/IF | IP | FCM
Application Details:
WB (1:2000), ICC/IF (1:100), IHC (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
Unconjugated
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science. 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry. 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell. 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.2, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog Calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
Applications:
WB | IHC | ICC/IF | IP | FCM
Application Details:
WB (1:2000), ICC/IF (1:100), IHC (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
Unconjugated
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science. 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry. 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell. 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:1000), IHC (1:100), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
Alkaline Phosphatase
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.2, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog Calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:2000), ICC/IF (1:100), IHC (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
Alkaline Phosphatase
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science. 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry. 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell. 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:1000), IHC (1:100), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
APC
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.2, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog Calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:2000), ICC/IF (1:100), IHC (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
APC
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science. 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry. 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell. 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:1000), IHC (1:100), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
ATTO 390
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.2, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog Calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:2000), ICC/IF (1:100), IHC (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
ATTO 390
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science. 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry. 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell. 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:1000), IHC (1:100), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
ATTO 488
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.2, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog Calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:2000), ICC/IF (1:100), IHC (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
ATTO 488
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science. 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry. 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell. 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:1000), IHC (1:100), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
ATTO 565
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.2, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog Calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:2000), ICC/IF (1:100), IHC (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
ATTO 565
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science. 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry. 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell. 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.4, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:1000), IHC (1:100), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
ATTO 594
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Calnexin, an abundant ~90kDa integral protein of the endoplasmic reticulum, is also referred to as IP90, p88 and p90 (1). It consists of a large 50kDa N-terminal calcium-binding luminal domain, a single transmembrane helix and a short acidic cytoplasmic tail (2, 3). Unlike its ER counterparts which have a KDEL sequence on their C-terminus to ensure ER retention (4), calnexin has positively charged cytosolic residues that do the same thing (3). Most ER proteins act as molecular chaperones and participate in the proper folding of polypeptides and their assembly into multi-subunit proteins. Calnexin together with calreticulin, plays a key role in glycoprotein folding and its control within the ER, by interacting with folding intermediates via their mono-glycosylated glycans (5, 6). Calnexin has also been shown to associate with the major histocompatibility complex class I heavy chains, partial complexes of the T cell receptor and B cell membrane immunoglobulin (7).
Product Type:
Antibodies
Format:
PBS pH7.2, 50% glycerol, 0.09% sodium azide
Storage Temp:
-20ºC
Host Animal:
Rabbit
Species Reactivity:
Hu | Ms | Rt | Bv | Mk | Ck | Dg | GP | Hm | Pg | Qu | Rb | Sh | Dr | Xe
Immunogen:
Dog Calnexin C-terminal synthetic peptide conjugated to KLH. Identical to human, mouse and rat calnexin sequences over these residues.
WB (1:2000), ICC/IF (1:100), IHC (1:100); optimal dilutions for assays should be determined by the user.
Target:
Calnexin
Conjugate:
ATTO 594
Research Area(s):
Cell Signaling | Tags and Cell Markers | Organelle Markers
Alternative Name(s):
Calnexin antibody, CALX_HUMAN antibody, CANX antibody, CNX antibody, FLJ26570 antibody, Histocompatibility complex class I antigen binding protein p88 antibody, IP90 antibody, Major histocompatibility complex class I antigen-binding protein p88 antibody, P90 antibody
1. Rajagopalan S., Xu Y., and Brenner M.B. (1994) Science. 263(5145): 387-90. 2. Tjoelker L.W., et al. (1994) Biochemistry. 33: 3229. 3. Schrag J. et al. (2001) Molecular Cell. 8(3): 633-644. 4. Janiszewski M. (2005) J. Biol Chem. 280(49): 40813-40819. 5. Elagoz A., Callejo M., Armstrong J., and Rokeach L. A. (1999) J. Cell Sci. 112: 4449-4460. 6. Otteken A. and Moss B. (1996) J Bio Chem. 271(1): 97-103. 7. Galvin K. et al. (1992) Proc Natl Acad Sci USA. 89(18): 8452-6.
Tarriff Code:
3002.15.0000
ADR Code:
Non-hazardous
UN Code for transport:
Non-hazardous
Country of Origin:
Canada
Cookies:
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
